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Abstract
Background: We previously discovered that tetracyclines increase the expression of lipid phosphate phosphatases
at the surface of cells. These enzymes degrade circulating lysophosphatidate and therefore doxycycline increases
the turnover of plasma lysophosphatidate and decreases its concentration. Extracellular lysophosphatidate signals
through six G protein-coupled receptors and it is a potent promoter of tumor growth, metastasis and chemo-resistance.
These effects depend partly on the stimulation of inflammation that lysophosphatidate produces.
Methods: In this work, we used a syngeneic orthotopic mouse model of breast cancer to determine the impact
of doxycycline on circulating lysophosphatidate concentrations and tumor growth. Cytokine/chemokine
concentrations in tumor tissue and plasma were measured by multiplexing laser bead technology. Leukocyte
infiltration in tumors was analyzed by immunohistochemistry. The expression of IL-6 in breast cancer cell lines
was determined by RT-PCR. Cell growth was measured in Matrigel™ 3D culture. The effects of doxycycline on
NF-κB-dependent signaling were analyzed by Western blotting.
Results: Doxycycline decreased plasma lysophosphatidate concentrations, delayed tumor growth and decreased
the concentrations of several cytokines/chemokines (IL-1β, IL-6, IL-9, CCL2, CCL11, CXCL1, CXCL2, CXCL9, G-CSF,
LIF, VEGF) in the tumor. These results were compatible with the effects of doxycycline in decreasing the numbers
of F4/80+ macrophages and CD31+ blood vessel endothelial cells in the tumor. Doxycycline also decreased the
lysophosphatidate-induced growth of breast cancer cells in three-dimensional culture. Lysophosphatidate-
induced Ki-67 expression was inhibited by doxycycline. NF-κB activity in HEK293 cells transiently expressing a NF-
κB-luciferase reporter vectors was also inhibited by doxycycline. Treatment of breast cancer cells with doxycycline
also decreased the translocation of NF-κB to the nucleus and the mRNA levels for IL-6 in the presence or absence
of lysophosphatidate.
Conclusion: These results contribute a new dimension for understanding the anti-inflammatory effects of
tetracyclines, which make them potential candidates for adjuvant therapy of cancers and other inflammatory diseases.
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Background
Chronic inflammation is one of the intrinsic features of the
tumor microenvironment, which makes it an important
hallmark of cancer development and progression [1–3].
Autotaxin (ATX) is a secreted enzyme, which is a key regu-
lator of inflammation through its production of lysopho-
sphatidate (LPA) from lysophosphatidylcholine [4, 5]. LPA
signals through six G protein-coupled receptors to
stimulate cell proliferation, survival, migration and
angiogenesis, which promote tumor growth [4, 6]. In-
creased ATX and LPA levels are also important in the
development of chronic inflammation in asthma, pul-
monary fibrosis, rheumatoid arthritis, atherosclerosis,
hepatitis, multiple sclerosis, Crohn’s disease and ulcera-
tive colitis [7–9].
Increased LPA signaling is closely associated with tumor
growth and cancer-related inflammation [10–13]. This is
because LPA induces the expression of inflammatory
cytokines through activating nuclear factor-κB (NF-κB)
[14, 15]. We reported that inflammatory cytokines from
breast tumors stimulate ATX production by adjacent
adipose tissue [11]. The consequently high LPA con-
centration enhances lymphocyte infiltration, which in-
creases the inflammatory status in the tumor. This
vicious cycle of LPA signaling increases the production
of inflammatory mediators, which further increases
tumor growth, metastasis and the development of
chemo-resistance [10, 11, 16]. Cancer-related inflam-
mation comprises a complicated crosstalk between can-
cer cells and leukocytes. The massive infiltration of
tumor associated macrophages (TAM), especially M2
macrophages, represents a poor prognosis in many
types of cancer [17–19]. In the tumor microenviron-
ment, TAMs originate from the monocyte lineage
through the action of cytokines, e.g., chemokine (C-C
motif ) ligand 2 (CCL2), secreted by stromal cells and
cancer cells [20, 21]. TAMs stimulate cancer cell prolif-
eration by secreting growth factors, e.g., epidermal
growth factor (EGF) [22] and platelet derived growth
factor (PDGF) [23]. TAMs also promote angiogenesis by
producing vascular endothelial growth factor (VEGF) [24]
and suppress antitumor immunity by secreting immune
regulatory molecules such as IL-10 [25] and transform
growth factor β (TGFβ) [26].
Treatment of mice that had breast cancer with a specific
ATX inhibitor, ONO-8430506, had an anti-inflammatory
effect. It decreased LPA level in plasma and tumors,
thereby decreasing the concentrations of 20 inflammatory
cytokines/chemokines in adipose tissue adjacent to the
tumor [10, 27]. An alternative way to regulate LPA levels
is through a family of enzymes named lipid phosphate
phosphatases (LPPs), which consists of three isoforms,
LPP1, LPP2 and LPP3 [28, 29]. LPPs dephosphorylate
extra-cellular LPA to monoacylglycerol, which terminates
LPA signaling. The expressions of LPP1 and LPP3 are de-
creased in many cancers, including breast cancer [28, 30].
We recently discovered that tetracyclines increase extra-
cellular LPA degradation by enhancing the stabilities of
LPP1, LPP2 and LPP3 in several breast cancer cell lines
and in non-transformed cells [31]. The clearance of LPA
from the circulation in rats was accelerated by doxycycline
treatment and LPA concentrations in mouse plasma were
decreased [31]. This tetracycline effect does not involve
the inhibition of matrix metalloproteinase activity [31].
Tetracyclines also show anti-inflammatory effects,
and their clinical use has been expanded from microbial
infection to inflammatory diseases including acne [32],
rosacea [33], perioral dermatitis [34] and gingivitis [35].
Effective use of tetracyclines has been reported in
rheumatoid arthritis [36], osteoarthritic cartilage [37],
allergen-induced inflammation and inflammatory skin
disorders [38].
Therefore, the effects of tetracyclines on LPA degrad-
ation and inflammation suggest that they may have
beneficial effects on cancer therapy. In the present study,
we demonstrated that doxycycline decreased breast
tumor growth in a syngeneic orthotopic mouse model.
Doxycycline treatment decreased plasma LPA levels and
the concentrations of several inflammatory mediators,
the infiltration of F4/80+ macrophages and blood vessel
formation in the tumor. Doxycycline also inhibited NF-
κB activation in breast cancer cells by decreasing phos-
phorylation of the inhibitor of κB (IκB) and nuclear
translocation of NF-κB. These results demonstrate that
doxycycline has a novel action in decreasing LPA signal-
ing, which contributes to its anti-inflammatory effects.
These actions provide new mechanisms that support the
use of tetracyclines as an adjuvant therapy for cancers
and other inflammatory diseases.
Results
Doxycycline delayed tumor growth and decreased the
numbers of tumor-associated macrophages and blood
vessels in a syngeneic orthotopic mouse model of breast
cancer
We recently discovered that doxycycline increased the
dephosphorylation of extracellular LPA in MDA-MB-
231, MCF-7 and 4T1 breast cancer cells by increasing
the expression of the LPPs on the cell surface [31]. This
explained why animals treated with doxycycline showed
increased clearance of LPA from the circulation and de-
creased plasma LPA levels. These results indicate that
doxycycline could have favorable effects on cancer treat-
ment, since LPA signaling is up-regulated in many
cancers.
We, therefore, used a syngeneic mouse model of breast
cancer to study the effects of doxycycline on tumor
growth. Doxycycline at 50 mg/kg/day was tolerated fairly
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well and it resulted in a loss of body weight of only
~10% after 15 days. Doxycycline treatment significantly
decreased tumor volume by ~25% and tumor weight by
~35%. (Fig. 1a, b). There was also a significant decrease
in tumor weight in the doxycycline-treated group of
~20% when it was expressed relative to body weight
(Additional file 1: Figure S1A). The inhibitory effect of
doxycycline on tumor growth was maintained for
24 days after inoculation (Additional file 1: Figure S1B).
The apparent decrease in the number of metastatic
nodules on lung surface 24 days after inoculation in
doxycycline-treated mice did not reach the level of stat-
istical significance (Additional file 1: Figure S1C). As
predicted, doxycycline treatment decreased plasma
LPA concentrations by ~26% (Fig. 1d), which can be
explained by the doxycycline-induced increase of LPP
activity on the cells surface [31]. ATX activity in
plasma was not affected significantly by doxycycline
(Fig. 1e).
Immunohistochemistry staining of the breast tumors
demonstrated that doxycycline treatment significantly
decreased the numbers of F4/80+ macrophages by ~50%
and CD31+ blood vessels in the tumor by ~30% (Fig. 1f,
g and h). There was no significant change in infiltration
of total CD45+ leukocytes, CD8+ cytotoxic T cells and
Foxp3+ regulatory T cells (Additional file 1: Figure S1D).
Fig. 1 Doxycycline delayed breast tumor growth, decreased plasma LPA concentration, inhibited F4/80+ macrophage infiltration and blood vessel
formation in the tumor. a. Tumor volume from day 5 to day 15 post inoculation of 4T1 cells. BALB/c mice were treated with doxycycline (Dox) at
50 mg/kg/day by i.p. injection. Control mice were given saline by i.p. injection. n = 6 for each group, * p < 0.05 relative to control. b. The difference in
tumor weight. n = 6 for each group, ** p < 0.01 relative to control. c. Image of the tumors from control and Dox treated mice. d. Plasma LPA
concentration of the mice with tumor. n = 6 for each group, * p < 0.05 relative to control. e. Plasma autotoxin (ATX) activity of control and Dox
treated mice. f. F4/80+ macrophage numbers per field detected by IHC in tumors from control and Dox treated mice. * p < 0.05 relative to
control. g. CD31+ blood vessel numbers per field detected by IHC in tumors from control and Dox treated mice. * p < 0.05 relative to control.
These were quantified by examining 5 different fields from each tumor and by using 6 mice per group. h. Representative images of IHC
staining for F4/80+ macrophages and CD31+ blood vessels in tumors from control and Dox treated mice. Scale bar = 100 μm. Results are
means ± SEM. Results were analyzed by a Student’s t-test
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Doxycycline decreased inflammatory cytokine levels in
plasma and tumor tissue
Since LPA is an important mediator of inflammation, we
next determined the levels of cytokines in the breast tumor.
Doxycycline treatment significantly decreased the concen-
trations of IL-1β, IL-6, IL-9, CXCL1, CXCL2, CXCL9,
CCL2, CCL11, G-CSF, LIF, and VEGF in the tumor (Fig. 2).
In addition, we measured the concentrations of G-CSF, IL-
1β, IL-6, CCL4 and TNFα in the plasma of the mice with
breast cancer. Only G-CSF was decreased significantly by
doxycycline treatment (Additional file 2: Figure S2).
Doxycycline decreased IL-6, CCL2 and CXCL2 expression
in 4T1 cells
Tumors are composed of cancer and stromal cells,
all of which express cytokines. Our previous work
Fig. 2 BALB/c mice treated with Doxycycline (Dox) at 50 mg/kg/day showed significantly decreased concentrations of IL-1β, IL-6, IL-9, CXCL1,
CXCL2, CXCL9, CCL2, CCL11, G-CSF, LIF and VEGF in the tumor. Concentrations of IL-1α, IL-2, IL-3, IL-4, IL-5, IL-7, IL-10, IL-12 (p40), IL-12 (p70), IL-13,
IL-15, IL-17, CXCL5, CXCL10, CCL3, CCL4, CCL5, GM-CSF, IFNγ, M-CSF and TNFα were not affected by Dox. n = 6 for each group. Results are means
± SEM, * p < 0.05, ** p < 0.01 relative to control. Results were analyzed by a Student’s t-test
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showed that LPA stimulated inflammatory cytokine
secretion by mouse 4T1 breast cancer cells [11].
Doxycycline decreased plasma LPA [31], which could
cause lower cytokine production by cancer cells. In
present study, LPA induced a rapid increase of IL-6
mRNA expression, which reached a peak at 1 h after
stimulation of 4T1 cells. Doxycycline treatment de-
creased IL-6 expression, even when LPA was absent
(Fig. 3a). This indicated that the inhibition of IL-6
expression by doxycycline was not entirely through
suppressing LPA signaling. Therefore, we used TNFα
as an agonist and doxycycline also inhibited TNFα-
induced IL-6 expression (Fig. 3b). Similar results
were observed in human MDA-MB-231 cells, in
which doxycycline decreased the expressions of IL-6
in the presence or absence of LPA or TNFα (Fig. 3c
and d). We also showed that doxycycline decreased
the secretions of IL-6, CCL2 and CXCL2 by 4T1
cells and this did not depend on the presence of
LPA (Fig. 4).
Doxycycline decreased NF-κB translocation and IκB
phosphorylation in breast cancer cells
Inflammatory signals from both LPA and TNFα recep-
tors can converge on NF-κB, which increases the expres-
sion of inflammatory cytokines, e.g., IL-6. We predicted
that doxycycline decreases inflammatory cytokine ex-
pression by inhibiting NF-κB-mediated transcription. As
expected, LPA and TNFα increased the translocation of
NF-κB to the nucleus in 4T1 cells. These effects were
inhibited by doxycycline (Fig. 5a and b). Doxycycline also
inhibited TNFα-induced translocation of NF-κB to the
nucleus in MDA-MB-231 cells (Fig. 5c). In agreement
with this, IκB phosphorylation and the degradation of total
IκB induced by TNFα were decreased by doxycycline
(Fig. 5d). Doxycycline decreased both the basal and
TNFα-induced ratio of luminescence in HEK293 cells
transiently transfected with NF-κB luciferase reporter and
Renilla luciferase vectors (Additional file 3: Figure S3).
Therefore, the anti-inflammation effect of doxycycline in-
volves decreases in NF-κB-induced transcription.
Fig. 3 Doxycycline (Dox) significantly decreased LPA and TNFα induced IL-6 mRNA expression in breast cancer cells. Cells were serum starved for
14 h in DMEM/0.1% BSA and then followed with LPA (1 μM) or TNFα (20 ng/ml) stimulation. For Dox-treated cells, 5 μg/ml of Dox was included
during serum starvation and stimulation. a. Time course of LPA induced IL-6 expression in 4T1 cells and the inhibition by Dox. b. Time course of
TNFα induced IL-6 expression in 4T1 cells and the inhibition by Dox. c. Time course of LPA induced IL-6 expression in MDA-MB-231 cells and the
inhibition by Dox. d. Time course of TNFα induced IL-6 expression in MDA-MB-231 cells and the inhibition by Dox. * p < 0.05 relative to control.
Results are means ± SEM from three independent experiments. Results were analyzed by ANOVA with an SNK posthoc test
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Doxycycline inhibited migration of mouse peripheral
blood mononuclear cells (PBMCs) and IκB
phosphorylation in RAW264.7 cells
The inhibition of macrophage infiltration in tumors ob-
served in Fig. 1d and e could have been caused by the
doxycycline-induced decrease in the concentrations of
chemo-attractants in the tumor (Fig. 2). It is also pos-
sible that doxycycline could directly inhibit the activa-
tion of macrophages [39]. We showed that doxycycline
significantly decreased the migration of mouse PBMCs
that was induced by LPA or CCL2 (Fig. 6a). Induction of
IκB phosphorylation and degradation by lipopolysac-
charide (LPS) in RAW264.7 macrophage cells were sup-
pressed by doxycycline (Fig. 6b, c, d).
Doxycycline did not affect LPA signaling downstream of
LPA receptor activation
LPPs control signaling by two distinct mechanisms: 1)
by decreasing extracellular LPA concentrations and 2)
by degrading a lipid phosphate formed downstream of
the activation of G protein coupled receptors, including
LPA receptors [40]. To determine how doxycycline in-
hibits LPA signaling, we used LPA to induce the phos-
phorylations of Akt and ERK in 4T1 cells. Doxycycline
at 10 μg/ml did not affect the phosphorylations of Akt
or ERK (Fig. 7a). Similarly, Ca2+-transients induced by
10 μM of LPA were not changed by doxycycline in
MDA-MB-231 cells (Fig. 7b).
Doxycycline does enhance LPA degradation outside of
cells [31]. However, this is a relatively slow process,
which would not be rapid enough to substantially de-
crease the availability of the 1 to 10 μM LPA used in the
transient stimulations in Fig. 7a, b. By contrast, doxycyc-
line did inhibit the effect of LPA in stimulating the pro-
liferation of 4T1 cells in 3-D culture over 9 days where
there was sufficient time each day to degrade extracellu-
lar LPA. The dependency of the doxycycline effect on
LPA was established since cell growth induced by
charcoal treated FBS (FBSC), in which LPA was se-
verely depleted, was not affected by doxycycline
(Fig. 7c). In monolayer culture, doxycycline also inhib-
ited Ki-67 expression stimulated by LPA in MDA-MB-
231 cells (Additional file 4: Figure S4). These results
demonstrate that it is the doxycycline-induced expres-
sion of the LPPs on the cell surface [31], which de-
creases external LPA availability that is responsible for
decreasing the LPA effects on cell growth.
Discussion
Our previous study demonstrated a novel action of tet-
racyclines in increasing the stability of the LPPs in can-
cer and non-transformed cells [31]. This increased the
expressions of LPP1, LPP2 and LPP3 at the surface of
cells, which increased the degradation of extracellular
LPA and lowered circulating LPA concentrations in
mice. Up-regulations of ATX, LPA receptors and LPA
levels coupled with decreased expression of LPP1 and
LPP3 are closely associated with the growth and metas-
tasis of many cancers [5, 28, 40]. Therefore, we deter-
mined if this novel effect of tetracyclines on LPP
expression could decrease breast tumor growth. We
showed that doxycycline decreased plasma LPA levels
and delayed tumor growth in a syngeneic mouse model
of breast cancer. LPA is also one of the critical triggers
of tumor-induced inflammation by inducing the produc-
tion of inflammatory cytokines in breast cancer cells
[11]. In agreement with this, the doxycycline-induced
decrease in plasma LPA was accompanied by a decrease
in the concentrations of several cyotkines/chemokines
(IL-1β, IL-6, IL-9, CCL2, CCL11, CXCL1, CXCL2,
CXCL9, G-CSF, LIF, VEGF) in the tumor.
LPPs have two mechanisms for attenuating LPA sig-
naling. First, LPPs on the plasma membrane degrade
extracellular LPA, which decreases the amount of exter-
nal LPA that can signal through its receptors [31].
Doxycycline specifically increases this ecto-activity of
Fig. 4 Doxycycline (Dox) significantly decreased the secretion of IL-6, CCL2 and CXCL2 by 4T1 cells. Cells were cultured with DMEM/10% FBS. The
medium was changed with DMEM/0.1% BSA with or without LPA (5 μM) and Dox (5 μg/ml or 10 μg/ml). Conditioned medium was collected
after incubation for another 24 h. Measurements were normalized to the cell protein. * p < 0.05 relative to cells without Dox and LPA treatment,
# p < 0.05 relative to cells treated with LPA but not Dox. Results are means ± SEM from three independent experiments. Results were analyzed by
ANOVA with an SNK posthoc test
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the LPPs, although it did not modify the rapid effects of
LPA in activating Ca2+-transients, phosphorylations of
ERK or Akt. This is explained since the ecto-LPP activ-
ity on plasma membranes would not have degraded suf-
ficient LPA in our short-term experiments to attenuate
rapid signaling. Doxycycline did, however, decrease the
longer-term action of LPA in stimulating cell prolifera-
tion in 3D culture. The second mode of action of the
LPPs is that increased expression of LPPs inside cells
blocks cell signaling downstream of LPA and other G-
protein coupled-receptors [28, 41]. This appears to in-
volve the degradation of lipid phosphates formed
downstream of receptor activation [42]. Consequently,
targeted overexpression of LPP1 inside cells does at-
tenuate LPA-induced activation of Ca2+-transients [30,
43]. In the case of human bronchial epithelial cells,
this effect blocked the phosphorylation of IκB and
translocation of NF-κB to the nucleus, which almost
completely prevented IL-8 secretion [43]. However,
this downstream effect on LPA receptor signaling was
Fig. 5 Doxycycline (Dox) inhibited LPA and TNFα-induced translocation of NF-κB p65 to the nucleus in breast cancer cells. Cells were serum
starved for 14 h in DMEM/0.1% BSA and then followed stimulation with 5 μM LPA or 20 ng/ml TNFα. For Dox-treated cells, 5 μg/ml of Dox was
included during serum starvation and stimulation. a. Time course of NF-κB translocation to nucleus induced by LPA in 4T1 cells and the effect of
Dox. b. Time course of NF-κB translocation to nucleus induced by TNFα in 4T1 cells and the effect of Dox. c. Time course of NF-κB translocation
to nucleus induced by TNFα in MDA-MB-231 cells and the effect of Dox. d. The effect of Dox on the time course of phospho-IκBα and total IκBα
by TNFα in MDA-MB-231 cells. * p < 0.05 relative to control. Results are means ± SEM from three independent experiments. Results were analyzed
by ANOVA with an SNK posthoc test
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Fig. 6 Effects of Doxycycline on PBMCs and RAW264.7 cells. a. Dox at 5 μg/ml suppressed the migration of mouse PBMCs induced by 1 μM of
LPA and 100 ng/ml of CCL2. * p < 0.05 relative to basal level, # p < 0.05 relative to control. b. The effect of Dox on time course of phosphor-IκBα
and total IκBα by 50 ng/ml of LPS in RAW264.7 cells. c. Quantification of phosphor-IκBα. d. Quantification of total IκBα. * p < 0.05 relative to control.
Results are means ± SEM from three independent experiments. Results were analyzed by ANOVA with an SNK posthoc test
Fig. 7 Doxycycline (Dox) did not affect signal transduction by transient LPA stimulation, but attenuated the long term effect of LPA on cell
growth. a. 4T1 cells were serum starved with DMEM/0.1% BSA and stimulated with 1 μM LPA for 5, 10 and 20 min. Dox at 10 μg/ml was included
in serum starvation and stimulation. LPA-induced stimulations of Akt and ERK phosphorylations were not affected by Dox. b. MDA-MB-231 cells were
serum starved with DMEM/0.1% BSA and stimulated with 10 μM LPA. Dox at 10 μg/ml was included in serum starvation. LPA-induced Ca2
+-mobilization was not affected by Dox. c. A three-dimensional culture system was established by layering 400 μl of 4T1 cell suspension (6000
cells in DMEM with 10% FBSC and 2% Matrigel™) over 150 μl Matrigel™ in an 8-well chamber with daily replacement with fresh medium containing LPA or
drugs. Dox decreased the stimulation of 4T1 cell colony formation by 5 μM LPA after incubation for 9 days. Scale bar = 1000 μm. *p< 0.05 relative to cells
without Dox and LPA treatment, # p< 0.05 relative to cells treated with LPA but not Dox. Results are means ± SEM from three independent experiments.
Results were analyzed by ANOVA with an SNK posthoc test
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not involved in the doxycycline effect on LPP expression,
which is increased LPP expression on the plasma mem-
brane and thus decreased external LPA concentrations.
NF-κB activation is stimulated by different receptors,
e.g., the toll like receptor family, the TNF receptor super
family and G protein-coupled receptors, including LPA
receptors [44]. The signals are transmitted through dif-
ferent pathways depending on the type of receptor acti-
vated, but they converge on IκB kinase (IKK) [45]. IKK
phosphorylates IκB, an NF-κB inhibitor that prevents
the translocation of NF-κB to the nuclear by binding to
it in a dephosphorylated state. Upon phosphorylation,
IκB is degraded through ubiquitination and this releases
NF-κB from the sequestration. NF-κB then enters the
nuclear and mediates the expression of genes for inflam-
matory cytokines [45]. Our study showed that doxycyc-
line suppressed both LPA- and TNFα-induced nuclear
translocation of NF-κB and blocked the LPA-induced
secretion of IL-6, CCL2 and CXCL2 in cancer cells.
TNFα-induced nuclear NF-κB transcriptional activity
was also inhibited by doxycycline. Under basal condition
without stimulation, doxycycline was able to decrease
the transcriptional activity of nuclear NF-κB by ~50%,
which explained the decreased IL-6 mRNA and secre-
tion of IL-6, CCL2 and CXCL2 by doxycycline when
LPA and TNFα were absent. However, the nuclear
translocation of NF-κB and IκB phosphorylation were
not affected significantly by doxycycline under this
basal condition. Although NF-κB nuclear translocation
is an important step in NFκB activation, modification
of nuclear NF-κB by various events including phos-
phorylation, ubiquitination, nitrosylation, acetylation
and interaction with different co-activators can affect
its activity [46, 47]. Therefore, doxycycline inhibited the
transcriptional activity of nuclear NF-κB, but did not
affect nuclear translocation of NF-κB under basal condi-
tion. Upon stimulation, doxycycline was able to inhibit
both the induced NF-κB translocation and transcriptional
activity. These results establish that doxycycline inhibited
NF-κB-mediated transcription independently of signaling
by LPA. Therefore, the anti-inflammatory activity of doxy-
cycline consists of at least two components: 1) A decrease
in the availability of LPA for stimulating inflammation and
2) Inhibition of NF-κB activation that also decreases the
production of inflammatory cytokines.
The chronic inflammatory milieu inside tumors polar-
izes TAMs to promote tumor growth [17–19]. For ex-
ample, TAMs secrete growth factors including EGF [22],
PDGF [23] and VEGF [24] to promote cancer cell prolif-
eration and blood vessel formation. TAMs also inhibit
the immune reaction of CD8+ T-cells against cancer
cells by producing IL-10 and TGFβ [26]. In our work,
doxycycline not only suppressed the cancer cell-derived
chemo-attractants for monocytes, e.g., IL-6 and CCL2,
but also directly impaired the migration activity of
mouse PBMCs. These actions on both cancer cells and
monocytes were compatible with the ~50% decrease of
macrophage infiltration in the tumor. Furthermore,
doxycycline blocked IκB phosphorylation and degrad-
ation in RAW264.7 macrophage cells in response to
LPS, suggesting that the expressions of NF-κB target
genes in TAMs were decreased. This could explain the
different cytokine profile in the tumors after doxycycline
treatment. Growth factors, e.g., G-CSF and VEGF, which
are controlled by NF-κB [48, 49], were also decreased in
the tumor by doxycycline. In many cancers, increased
infiltration of tumors with TAMs is normally associated
with a poor prognosis and the efficacy of targeting mac-
rophages has been verified in preclinical studies for
cancer therapy [50, 51]. The capability of doxycycline
to selectively suppress TAM infiltration could maintain
the anti-tumoral effects of CD8+ cytotoxic T-cells.
The effects of doxycycline that we reported in mice
were obtained at a dose of 50 mg/kg/day. The equivalent
dose for human is ~4 mg/kg/day calculated by equiva-
lent surface area dosage conversion factor, which is
240 mg/day for 60 kg of body weight. The typical dose
of doxycycline is 100–200 mg/day and the maximum
dose is 300 mg/day for more serious infections, such as
syphilis. Therefore, the dose of doxycycline used in this
study is within the therapeutic range, which is used
clinically.
Conclusion
The present work established the importance of a
novel dimension of tetracycline action. Doxycycline is
a relatively inexpensive, commonly used and well-
tolerated compound, which has multiple functions in
addition to its anti-microbial activity. It is well known
that tetracyclines inhibit matrix metalloproteinase ac-
tivities [52]. These enzymes degrade extracellular
matrix and this is involved in cancer cell invasion and
migration. Several reports showed that tetracyclines
have anti-neoplastic activity [51, 53, 54], but the
mechanisms for this are poorly understood. This
paper, together with our previous work [31], demon-
strates a novel effect of tetracyclines in decreasing
extracellular LPA concentrations by increasing the
“ecto-activity” of the LPPs. This effect could be im-
portant for the treatment of cancers and other inflam-
matory conditions since LPA is an important regulator
of inflammation through activation of NF-κB. In
addition, doxycycline had a further action in decreas-
ing NF-κB activation independently of the LPA signal.
These combined actions of doxycycline make it a po-
tential candidate for an adjuvant therapy for cancer
and other inflammatory diseases.
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Methods
Reagents and cell lines
Oleoyl-LPA (233019) was from Avanti Polar Lipids
(Alabaster, AL). Doxycyclinehyclate (0219895525) was
from MP Biomedicals (Solon, OH). Fatty acid-free albu-
min from bovine serum (A8806), mouse anti tubulin
(T6074) antibody, probenecid (P8761), Calcein AM
(C1359), OptiPrep™ density gradient medium (D1556),
lipopolysaccharides (L3012) and protease inhibitor cock-
tail (P8340) were from Sigma (St. Louis, MO). Rabbit anti
CD45 (ab10558), rabbit anti Foxp3 (ab54501), rabbit anti
CD31 (ab28364), Alexa Fluor 488 conjugated anti rabbit
IgG (ab150077) and HRP conjugated anti rat IgG (ab6734)
antibodies were from Abcam (Toronto, ON, Canada); Rat
anti F4/80 (14–4801), rat anti CD8α (14–0808) antibodies
were from eBioscience (San Diego, CA); mouse anti
phospho-Akt (4051), rabbit anti Akt (4691), mouse anti
phospho-ERK (9106), rabbit anti ERK (9102), mouse anti
IκB (4814), rabbit anti phosphor-IκB (Ser32) (2859), rabbit
anti Ki-67 (D3B5) and rabbit anti NF-κBp65 (8242) anti-
bodies were from Cell Signaling Technology (Danvers,
MA); Rabbit anti Lamin A/C (sc-20681) was from Santa
Cruz (Dallas, TX). Fura-2 AM (F-1201) and F127 (P-6867)
were from Life Technologies (Grand Island, NY). HRP
conjugated anti rabbit IgG antibody and DAB was from
DAKO (Carpinteria, CA). Matrigel™ (354230/354234) was
from Corning (Corning, NY). Recombinant human TNFα
(Z100857), recombinant mouse TNFα (Z200217), reverse
transcription master mix (G490) and EvaGreen qPCR
master mix (MasterMix-ER) were from Applied Biological
Materials Inc. (Richmond, BC, Canada). Human mam-
mary carcinoma cell lines MDA-MB-231, mouse mam-
mary carcinoma cell line 4T1, mouse macrophage cell line
RAW264.7, and HEK (human embryonic kidney) 293 cells
were from ATCC (Manassas, VA). Cells were cultured in
Dulbecco’s Modified Eagle Medium (DMEM) with 10%
FBS.
Real-time PCR and western blotting
IL-6 mRNA levels were determined by qRT-PCR using
glyceraldehyde 3-phosphate dehydrogenase (GAPDH)
and cyclophilin A (CycA) as reference mRNA. Protein
levels were measured by Western blotting as described
previously [30]. Immunoblots were analyzed by Odyssey
infrared imaging system (LI-COR Biosciences, NE).
Intracellular Ca2+-mobilization assay
MDA-MB-231 cells were serum starved overnight and de-
tached by PBS containing 2 mM EDTA and 0.1% (w/v)
fatty acid-free BSA, pH 7.4. Cells were washed and resus-
pended in Ca2+-, Mg2+- and phenol red-free Hank’s buffer
containing 2.5 mM probenecid and 0.1% (w/v) fatty acid-
free BSA. Cells were labeled with 2 mM Fura-2 AM plus
0.02% (w/v) F127, and incubated in the dark at 20 °C for
40 min. Following washing, cells were resuspended in the
same buffer at 5x105 cells/ml, and 2 ml of cell suspension
was loaded into a quartz cuvette for fluorescence meas-
urement using a fluorometer (C43/2000, PTI, NJ). LPA
at 10 μM was used for stimulation. The ratio of emis-
sion intensity at 510 nm that was caused by 340 and
380 nm excitation was used to calculate Ca2+-mobilization.
NF-κB translocation assay
MDA-MB-231 and 4T1 cells were cultured in 10-cm
dishes and serum starved over night when reach 80%
confluent. Doxycycline was added together with the star-
vation medium. Cells were stimulated on the next day
with 5 μM of LPA or 20 ng/ml of TNFα for 0.5, 1 and
2 h. Cells were washed twice with ice-cold PBS followed
by adding 0.5 ml of lysis buffer: 10 mM HEPES; pH 7.5,
10 mM KCl, 0.1 mM EDTA, 1 mM dithiothreitol (DTT),
0.5% Nonidet-40 and protease inhibitors. Cells were col-
lected by scraping and kept on ice for 30 min. After cen-
trifuge at 12,000 g for 10 min, the supernatants were
collected as a cytoplasmic fraction and the nuclear pel-
lets were washed with lysis buffer for 3 times, and then
resuspended in nuclear extraction buffer containing
20 mM HEPES (pH 7.5), 400 mM NaCl, 1 mM EDTA,
1 mM DTT and protease inhibitors and incubated on ice
for 30 min. The supernatant was collected by centrifuga-
tion at 12,000 g for 15 min at 4 °C as nuclear extract.
The level of NF-κB was determined by western blotting.
Cell proliferation assay in three-dimensional culture
4T1 cells were suspended in DMEM (1.5×104 cells/ml)
supplemented with 2% (v/v) growth factor-reduced
Matrigel™ and 10% FBSC. Cell suspension (400 μl/well)
was put onto the top of a thin layer of Matrigel™
(150 μl/well) in 8-well chamber slides (177402, Thermo
Scientific, Burlington, ON, Canada). LPA at 5 μM and
doxycycline at 5 μg/ml or 10 μg/ml were applied. Cells
were grown for 9 days with daily replacement with fresh
medium containing LPA and drugs, and fixed with 4%
(w/v) paraformaldehyde. Phase-contrast images were ac-
quired using an AMG EVOS digital inverted microscope
(Electron Microscopy Sciences, PA). The average size of
cell colonies was measured by ImageJ software.
Mouse tumor model
A syngeneic orthotopic mouse breast cancer model was
established using 4T1 cells as previously reported [30].
All procedures were performed in accordance with the
Canadian Council of Animal Care as approved by the
University of Alberta Animal Welfare Committee. Fe-
male BALB/c mice were given doxycycline 50 mg/kg/day
by i.p. injection. Control mice were given saline by i.p.
injection. Tumor growth was monitored by two orthog-
onal caliper measurements and tumor volume was
Tang et al. Molecular Cancer  (2017) 16:36 Page 10 of 13
estimated from width2 × length/2. After sacrificing the
mice, blood and tumors were collected. Lungs were fixed
with 10% formalin and then stained with India ink. Nod-
ules on the surface were counted.
Immunohistochemistry
Tumors were fixed with 10% formalin followed with par-
affin embedding and sectioning. Sample treatment and
immuno-staining were performed according to the stand-
ard procedure. For F4/80 staining, 0.05% trypsin treatment
at 37 °C for 10 min was applied for antigen retrieval. For
other antibodies, heating with Tris/EDTA, pH 9.0 in a
pressure cooker was used for antigen retrieval. Positive
staining events for CD45, CD8a, F4/80, Foxp3 and CD31
were selected and counted by ImageJ software. The aver-
age counts in 5 fields were calculated for each sample.
Measurement of plasma LPA concentrations
Mouse blood was collected by cardiac puncture using an
EDTA coated syringe. Plasma LPA concentration was
measured as described previously [27]. Blood samples
were centrifuged at 14,000 rpm for 1 min and plasma
was collected. Plasma was treated with isotope labeled
C17:0-LPA as internal standards and lipid phosphates
were extracted into butan-1-ol. Lysophospholipids were
measured by LC/MS with electrospray ionization in the
negative ion mode using an Agilent 1200 series LC system
coupled to a 3200 QTRAP mass spectrometer (AB Sciex,
Concord, ON, Canada). The concentrations of different LPA
species (C16:0-LPA, C20:4-LPA, C18:0-LPA and C18:1-LPA)
were summed as total LPA concentration in plasma.
Measurement of ATX activity
ATX activity was measured in 50 μl by the choline re-
leased from lysophosphatidylcholine (LPC) as previous
reported [27]. Ten μl of plasma was mixed with 15 μl of
buffer A (100 mM Tris-HCl, pH 9.0; 500 mM NaCl;
500 mM MgCl2; and 0.05% v/v Triton X-100) and prein-
cubated at 37 °C for 30 min. Samples were then mixed
with 25 μl of 6 mM C14:0-LPC in buffer A and incu-
bated for 6 h at 37 °C when 20 μl samples were pipetted
in duplicate into a 96-well plate and incubated at 37 °C
for 20 min with 90 μl/well of buffer C [9.65 ml buffer B
(100 mM Tris-HCl, pH 8.5, and 5 mM CaCl2), 110 μl of
30 mM TOOS (N-ethyl-N-(2-hydroxy-3-sulfopropyl)-3-
methylaniline, sodium salt, dehydrate; Dojindo Molecular
Technologies, Rockville, MD, USA), 110 μl of 50 mM
4-aminotipyrine, 6.6 μl of 1000 U/ml horseradish per-
oxidase, and 110 μl of 300 U/ml choline oxidase]. Cho-
line formation was measured at 550 nm. Activity
measurements were normalized to protein content.
Multiplex cytokine/chemokine measurements
Cytokines, chemokines, and growth factors were ana-
lyzed by Eve Technologies Corp. (Calgary, AB, Canada),
with a Milliplex Mouse Cytokine/Chemokine 32-plex kit
(Millipore, MO), according to the manufacturer’s proto-
col, on a Luminex 100 system (Luminex, Austin, TX).
Tissue specimens (10–25 mg) were homogenized in
200 μl of 20 mM Tris-HCl (pH 7.5) buffer with 0.5%
Tween 20, 150 mM NaCl, and protease inhibitors and
centrifuged for 10 min at 4 °C, and the supernatant was
transferred to a fresh tube. Protein content was mea-
sured using the bicinchoninic acid protein assay
(Thermo Fisher Scientific; IL). For supernatant analysis,
conditioned media were centrifuged before multiplex
analysis. Measurements were normalized to the cell pro-
tein. Plasma samples were diluted with an equal volume
of PBS before analysis.
Separation of mouse PBMCs and the transwell
migration assay
Blood was collected by cardiac puncture in EDTA-coated
tubes from 10 mice. Blood was diluted at 1:1 (v/v) with
tricine-buffered saline (TBS): 0.85% NaCl, 10 mM Tricine-
NaOH, pH7.0. A density barrier was prepared by mixing
OptiPrep™ with TBS and water at volume ratio of 45:155:31
respectively. One ml of the density barrier was added in a
15-ml centrifuge tube followed by adding 2 ml of diluted
blood on the top of it. Tubes were centrifuged at 700 g for
20 min at 20 °C. The PBMC band was collected at the
interface. Contaminating red blood cells were removed
using a red blood cell lysis buffer consisting of: 155 mM
NH4Cl, 10 mM KHCO3, 0.1 mM EDTA, pH 7.3. The
PBMC pellet was washed twice with RPMI medium.
PBMCs were cultured in RPMI with 0.1% BSA. Cells were
pre-treated with 5 μg/ml doxycycline for 12 h before the
experiment. PBMCs were labeled with 5 μM calcein-AM at
37 °C for 30 min. Cells were washed 3 times with RPMI
and resuspended in RPMI with 0.1% BSA at 5×106 cells/ml.
The transwell assay was performed using a 96-well Boyden
chamber as reported previously [30]. LPA at 1 μM or CCL2
at 100 ng/ml were added in the lower chambers and 100 μl
of cell suspension was added into the upper chamber.
The chambers were incubated at 37 °C in a tissue cul-
ture incubator for 90 min. Cells that migrated into the
lower chamber were quantified with a plate reader
(Fluoroskan Ascent, ThermoFisher Scientific, Burlington,
ON, Canada) at Ex488/Em510.
Statistical analysis
Results were analyzed by Student’s t-test or by
ANOVA for multiple comparisons followed by
Student-Newman-Keuls (SNK) test. p < 0.05 was con-
sidered statistically significant.
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